SCHEMBL10087249

SCHEMBL10087249

CNC(C)(C)Cc1ccc(F)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.63
CYP2D6 P10635 1/20 0.63
TAAR1 Q96RJ0 3/20 0.47
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.41
CASR P41180 2/20 0.40
DPP4 P27487 1/20 0.40
LATS1 O95835 1/20 0.40
LATS2 Q9NRM7 1/20 0.40
IDO1 P14902 2/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
MMP2 P08253 1/20 0.36
MMP8 P22894 1/20 0.36
MMP12 P39900 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.36
PLA2G1B P04054 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
ESR1 P03372 1/20 0.35
AGXT P21549 1/20 0.35
AOC3 Q16853 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21034644 0.78 LOXL2 (0.40) LMNACYP2D6TAAR1KDM4EHPGD
SCHEMBL10087170 0.78 CASR (0.44) LMNACYP2D6TAAR1KDM4EHPGD
Mephentermine SCHEMBL121178 0.77 LMNA (1.00) LMNACYP2D6TAAR1KDM4E
SCHEMBL72988 0.77 ESR1 (0.58) LMNATAAR1KDM4EHPGDIDO1
SCHEMBL2615503 0.77 ESR1 (0.58) LMNATAAR1KDM4EHPGDIDO1
SCHEMBL8824455 0.76 KDM4E (0.42) LMNACYP2D6TAAR1KDM4EHPGD
SCHEMBL14004086 0.75 LMNA (0.59) LMNACYP2D6TAAR1CASRIDO1
SCHEMBL5383349 0.75 TAAR1 (0.48) LMNACYP2D6TAAR1KDM4EHPGD
SCHEMBL9718295 0.75 KDM4E (0.57) LMNACYP2D6KDM4EHPGDDPP4
SCHEMBL21034645 0.75 HPGD (0.42) LMNACYP2D6TAAR1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170848-B1 PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES ASTRAZENECA AB (SE) 2014-10-22 EP disclosed
US-8299246-B2 N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses ASTRAZENECA AB (SE) 2012-10-30 US disclosed
US-8198311-B2 Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-12 US disclosed
US-8124634-B2 CB1 receptor modulators 7TM PHARMA A/S (DK) 2012-02-28 US disclosed
US-20100075961-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-03-25 US disclosed
US-20100010061-A1 CB1 RECEPTOR MODULATORS 7TM PHARMA A/S (DK) 2010-01-14 US disclosed
WO-2007020502-A2 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PHARMACIA & UPJOHN COMPANY LLC (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075961-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFRKB, NR0B1, NFKB2 LMNA 4134/4885CYP2D6 2403/4885TAAR1 1880/4885
US-20100010061-A1 CB1 RECEPTOR MODULATORS CNR1, CNR2, GPR6 LMNA 4443/4885CYP2D6 893/4885TAAR1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.